Yahoo News - Latest News & Headlines
GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business. Emma Walmsley, who took over in April, said GSK would in future allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.
No comments:
Post a Comment